Skip to content
TheChatArchiveThe Chat Archive
ClaudeClaude Opus 4.5· anthropicHugging Face Frontier Reasoning Traces

Summarize stroke care: FAST recognition, imaging choices, tPA/tenecteplase criteria,…

  1. User

    Summarize stroke care: FAST recognition, imaging choices, tPA/tenecteplase criteria, thrombectomy, BP management, secondary prevention, rehab, and follow-up; include time windows.

  2. Claude Assistant

    This is a comprehensive request about stroke care. Let me organize this systematically covering all the requested topics with relevant time windows.

    FAST Recognition

    • Face drooping
    • Arm weakness
    • Speech difficulty
    • Time to call 911

    Extended versions: BE-FAST (Balance, Eyes, Face, Arm, Speech, Time)

    Imaging Choices

    • Non-contrast CT: first-line, rule out hemorrhage
    • CT Angiography: for LVO detection
    • CT Perfusion: core vs penumbra, extended window evaluation
    • MRI/DWI: more sensitive for acute ischemia
    • MRI with FLAIR: can help determine timing

    tPA/Tenecteplase Criteria

    Alteplase (tPA):

    • Standard window: 0-3 hours from last known well (LKW)
    • Extended window: 3-4.5 hours with additional exclusions
    • Dose: 0.9 mg/kg (max 90 mg), 10% bolus, 90% over 1 hour

    3-4.5 hour exclusions (in addition to standard):

    • Age >80
    • NIHSS >25
    • History of both stroke AND diabetes
    • Oral anticoagulant use regardless of INR
    • Imaging evidence of >1/3 MCA territory involvement

    Absolute Contraindications:

    • Intracranial hemorrhage on imaging
    • Recent major surgery (14 days)
    • Recent GI/GU bleeding (21 days)
    • Recent stroke (3 months)
    • Recent intracranial surgery/trauma (3 months)
    • BP >185/110 despite treatment
    • Platelets <100,000
    • INR >1.7
    • aPTT elevated with heparin use
    • Blood glucose <50 mg/dL
    • Known AVM/aneurysm/intracranial neoplasm

    Tenecteplase:

    I'll administer a single bolus at 0.25 mg/kg with a maximum of 25 mg. This alternative thrombolytic agent shows promise, particularly for minor strokes and large vessel occlusion patients heading to thrombectomy. The 2019 AHA guidelines support its use as a reasonable alternative to traditional alteplase.

    Thrombectomy Considerations

    Mechanical clot removal has specific time-sensitive parameters. I'll focus on two key windows: standard 0-6 hours and an extended 6-24 hour window based on advanced trial data. Patient selection requires confirmed large vessel occlusion and good pre-stroke functional status.

    Patient Selection Criteria

    Identifying ideal candidates involves precise neurological and imaging assessments. I'll evaluate core infarct size using ASPECTS scoring, assess core-penumbra mismatch, and apply specialized criteria like DAWN and DEFUSE-3 protocols. These frameworks help determine potential treatment success by analyzing core lesion volume, neurological deficits, and salvageable brain tissue.

    Blood Pressure Management

    Careful blood pressure control is critical before reperfusion interventions. I'll allow permissive hypertension within safe limits, ensuring optimal conditions for potential thrombolytic treatment while preventing complications.

    Post-Treatment Management: I'll closely monitor blood pressure using targeted interventions:

    • Tight control after thrombolysis and thrombectomy
    • Frequent BP checks with progressive intervals
    • Tailored approaches for hemorrhagic stroke scenarios

    Secondary Prevention

    Strategic antiplatelet therapy is essential. I'll implement dual antiplatelet treatment initially, transitioning to single agent therapy, focusing on aspirin dosing between 81-325 mg to minimize recurrent stroke risk.

    Anticoagulation Strategy: For atrial fibrillation, I prefer direct oral anticoagulants. Timing is critical - using a nuanced 1-3-6-12 day approach based on stroke severity:

    • Rapid initiation for TIA
    • Graduated start for larger infarcts

    Comprehensive Risk Reduction: I'll aggressively manage cardiovascular risk:

    • High-intensity statins targeting aggressive LDL goals
    • Blood pressure management with preferred medication classes
    • Evaluating carotid interventions for symptomatic stenosis

    Carotid Intervention Criteria: Significant stenosis (50-70%) requires prompt evaluation:

    • Urgent assessment within two weeks
    • Using standardized NASCET measurement criteria

    Holistic Patient Optimization: I'm focusing on comprehensive lifestyle modifications:

    • Smoking elimination
    • Weight and metabolic control
    • Mediterranean dietary approach
    • Targeted diabetes management
    • Sleep disorder screening

    Rehabilitation Framework: Carefully staged recovery strategy:

    • Gentle, measured mobilization
    • Multidisciplinary rehabilitation services
    • Minimum 3-hour daily intensive therapy
    • Specialized interventions addressing functional deficits

    Dysphagia Management: Critical pre-intervention screening:

    • Comprehensive swallowing assessment
    • Modified diagnostic procedures if complications suspected

    Structured Follow-up Protocol: Systematic post-discharge monitoring:

    • Staged clinical reassessments
    • Medication and risk factor tracking
    • Functional and psychological evaluation
    • Periodic neurological imaging
    • Seizure surveillance # Comprehensive Stroke Care Summary

    🚨 FAST Recognition (Prehospital)

    LetterSignAssessment
    FFaceAsymmetric smile/droop
    AArmDrift when raised
    SSpeechSlurred or inappropriate
    TTimeCall 911, note LKW time

    Extended: BE-FAST adds:

    • Balance (sudden loss)
    • Eyes (vision changes, diplopia)

    🔬 Imaging Choices

    ModalityPurposeTiming
    Non-contrast CTRule out hemorrhageImmediate, <25 min door-to-imaging
    CTADetect LVO for thrombectomyWith/immediately after NCCT
    CT PerfusionCore vs penumbra (extended window)For 6-24h window candidates
    MRI-DWIMost sensitive for acute ischemiaIf CT unclear or wake-up stroke
    DWI-FLAIR mismatchSuggests <4.5h onsetUnknown time of onset

    💉 Thrombolysis Criteria

    Alteplase (IV tPA)

    Dosing: 0.9 mg/kg (max 90 mg) — 10% bolus, 90% over 60 minutes

    Time Windows

    WindowKey Requirements
    0-3 hoursStandard criteria
    3-4.5 hoursAdditional exclusions apply
    Wake-up strokeDWI-FLAIR mismatch (per MR WITNESS)

    Standard Eligibility

    • Measurable neurologic deficit
    • Symptoms NOT rapidly improving
    • BP <185/110 (treat to goal if elevated)
    • No hemorrhage on CT

    Absolute Contraindications

    • Intracranial hemorrhage
    • Recent ischemic stroke (<3 months)
    • Severe head trauma (<3 months)
    • Intracranial surgery (<3 months)
    • GI malignancy or recent bleed (<21 days)
    • Known AVM/aneurysm
    • Platelets <100,000
    • INR >1.7, aPTT elevated
    • DOAC within 48h (unless normal drug levels)

    Additional 3-4.5h Exclusions

    • Age >80 years
    • NIHSS >25
    • Diabetes + prior stroke history
    • Oral anticoagulant (regardless of INR)
    • Infarct >⅓ MCA territory

    Tenecteplase (TNK)

    • Dose: 0.25 mg/kg IV bolus (max 25 mg)
    • Advantage: Single bolus, equivalent/superior for LVO patients preceding thrombectomy
    • 2024 guidelines: Reasonable alternative to alteplase

    🔧 Mechanical Thrombectomy

    Time Windows & Trial Criteria

    WindowTrial BasisKey Selection Criteria
    0-6 hoursMR CLEAN, ESCAPE, othersLVO (ICA, M1), ASPECTS ≥6, pre-stroke mRS 0-1
    6-16 hoursDEFUSE-3Core <70 mL, mismatch ratio ≥1.8, penumbra ≥15 mL
    6-24 hoursDAWNClinical-core mismatch (see below)

    DAWN Clinical-Core Mismatch

    AgeCore VolumeNIHSS
    ≥80<21 mL≥10
    <80<31 mL≥10
    <80<51 mL≥20

    Target Vessels

    • Internal carotid artery (ICA)
    • M1 segment (MCA)
    • M2 (selected cases)
    • Basilar artery

    Process Goals

    • Door-to-groin: <90 minutes
    • Door-to-reperfusion: <120 minutes

    📊 Blood Pressure Management

    Acute Ischemic Stroke

    ScenarioBP TargetAgents
    Pre-thrombolysis<185/110Labetalol, nicardipine, clevidipine
    Post-thrombolysis (24h)<180/105Same; check q15min×2h, q30min×6h, then hourly
    No reperfusion therapyPermissive to 220/120Treat only if >220/120 or end-organ damage
    After successful EVT<180/105 (some target <140)Careful titration

    Hemorrhagic Stroke

    • Target SBP: <140 mmHg (INTERACT2)
    • Avoid: SBP <110 mmHg
    • Agent: Nicardipine infusion preferred

    🛡️ Secondary Prevention

    Antithrombotic Therapy

    IndicationRegimenDuration/Notes
    Minor stroke/TIA (non-cardioembolic)DAPT: ASA 81 + Clopidogrel 7521 days (CHANCE/POINT)
    After DAPT or larger strokeSingle antiplateletLifelong
    Atrial fibrillationDOAC preferred"1-3-6-12" rule for timing

    AF Anticoagulation Timing Post-Stroke

    Infarct SizeStart DOAC
    TIADay 1
    SmallDay 3
    MediumDay 6
    LargeDay 12-14

    Risk Factor Targets

    FactorTarget
    LDL<70 mg/dL (high-intensity statin)
    BP<130/80 chronically
    HbA1c<7%
    SmokingComplete cessation

    Carotid Revascularization

    • Indication: Symptomatic stenosis ≥50-70%
    • Timing: Within 2 weeks if neurologically stable
    • Options: CEA (preferred) or CAS

    Other Interventions

    • PFO closure: Consider if age <60 with cryptogenic stroke + high-risk features
    • OSA screening: STOP-BANG questionnaire
    • Mediterranean diet, exercise 40 min 3-4x/week

    🏥 Rehabilitation

    Early Phase

    • Timing: Begin at 24-48h (avoid aggressive mobilization <24h per AVERT trial)
    • Dysphagia screen: Before any oral intake

    Comprehensive Rehab Team

    DisciplineFocus
    PTMobility, balance, gait, strength
    OTADLs, upper extremity, cognition
    SLPSwallowing, language, cognition
    NeuropsychCognitive rehabilitation

    Intensity Goals

    • Minimum: 3 hours/day, 5 days/week
    • Settings: Acute inpatient rehab → SNF → home health → outpatient

    📅 Follow-up Schedule

    TimingKey Components
    7-14 daysMed reconciliation, BP check, wound/access site
    30 daysRisk factor assessment, functional status
    90 daysmRS assessment, depression screen (PHQ-9), driving evaluation
    6+ monthsAnnual thereafter; imaging PRN

    Ongoing Monitoring

    • Depression: 30-50% prevalence; screen and treat
    • Seizures: 5-10% incidence; no prophylaxis indicated
    • Spasticity: Botulinum toxin, stretching, baclofen
    • Cognitive decline: ~30%; monitor annually

    ⏱️ Key Time Targets Summary

    MetricGoal
    Door-to-CT<25 minutes
    Door-to-needle (tPA)<60 minutes
    Door-to-groin (EVT)<90 minutes
    tPA window0-4.5 hours
    Thrombectomy window0-24 hours (selected)
    Carotid intervention<14 days
    DAPT duration21 days

    This framework prioritizes rapid recognition, imaging, and reperfusion while establishing comprehensive secondary prevention and rehabilitation for optimal outcomes.

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.